AstraZeneca (LON:AZN) Stock Crosses Above 200 Day Moving Average – What’s Next?

AstraZeneca PLC (LON:AZN) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of £113.89 ($147.32) and traded as high as £120.20 ($155.48). AstraZeneca shares last traded at £119.94 ($155.14), with a volume of 1,437,588 shares traded.

Analyst Ratings Changes

Several research firms have weighed in on AZN. Berenberg Bank reiterated a “buy” rating and issued a GBX 140 ($1.81) price target on shares of AstraZeneca in a research report on Monday, January 27th. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research report on Friday, March 7th. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research report on Wednesday, February 19th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of GBX 7,542.80 ($97.57).

AstraZeneca Stock Up 0.9 %

The stock has a market capitalization of £230.77 billion, a P/E ratio of 32.88, a P/E/G ratio of 0.86 and a beta of 0.17. The company’s 50-day moving average price is £114.34 and its 200 day moving average price is £113.89. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.